Abacavir/dolutegravir/lamivudine, sold under the brand name Triumeq among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. It is a combination of three medications with different and complementary mechanisms of action: abacavir (reverse transcriptase inhibitor), dolutegravir (integrase inhibitor) and lamivudine (nucleoside analog reverse transcriptase inhibitor).The medication was developed by ViiV Healthcare and was approved for use in the United States and in the European Union in 2014.Abacavir is a nucleotide reverse transcriptase inhibitor. Specifically, abacavir is a guanosine analogue that interferes with HIV viral RNA-dependent DNA polymerase, ultimately resulting in inhibition of replication of HIV. Dolutegravir inhibits the HIV replication cycle by binding to the integrase active site and inhibiting the strand transfer step of HIV-1 DNA integration. Lamivudine is a cytosine analogue that inhibits HIV reverse transcription by terminating the viral DNA chain. Medical uses
Abacavir/dolutegravir/lamivudine is indicated for the treatment of HIV/AIDS in adults and adolescents aged 12 years of age and older who weigh at least 40 kilograms (88 lb). Adverse effects
The following adverse reactions were reported in <2% of patients:
Central nervous system: drowsiness, lethargy, nightmares, sleep disorders, suicidal ideation
Dermatologic: pruritus
Endocrine and metabolic: high levels of triglycerides
Gastrointestinal: abdominal distention, abdominal distress, abdominal pain, lack of appetite, stomach upset, flatulence, gastroesophageal reflux disease, upper abdominal pain, vomiting
Hepatic: hepatitis
Neuromuscular and skeletal: joint pain, muscle inflammation
Kidney: chronic kidney disease
Miscellaneous: feverSee individual agents as well as other combination products for additional information. Pregnancy
Abacavir/dolutegravir/lamivudine should only be used in pregnancy if the potential benefits outweigh the risks.
Patients usually develop a burning, pruritic sensation before the infection erupts. A physical exam shows vesicles and vesicopustules, along with pain and erythema. It is important to not confuse this with a felon or a paronychia as incision and drainage of herpetic whitlow could result in a secondary bacterial infection and failure to heal. Onychomycosis is a fungal infection of the nail that causes whitish-yellowish discoloration. Sometimes, it is difficult to treat and requires oral antibiotics instead of topical. Nail psoriasis  can affect the fingernails and toenails. It may cause thickening of the nails with areas of pitting, ridges, irregular contour, and even raising of the nail from the nail bed. Squamous-cell carcinoma is mainly cancer of the skin, but can also affect the nail bed. It is a rare malignant subungual tumor subject to misdiagnosis as chronic paronychia. Treatment
When no pus is present, warm soaks for acute paronychia are reasonable, though evidence to support its use is lacking.Chronic paronychia is treated by avoiding whatever is causing it, a topical antifungal, and a topical steroid. In those who do not improve following these measures, oral antifungals and steroids may be used or the nail fold may be removed surgically. Antibiotics
No strong evidence has been found to recommend topical vs. oral antibiotics, and this may be physician-dependent based on experience. Antibiotics used should have S. aureus coverage. Topical antibiotics used may be a triple antibiotic ointment, bacitracin, or mupirocin.